Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 22;2012(1):26.
doi: 10.1186/1687-9856-2012-26.

Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome

Emily K Sims  1 , Sally Garnett, Franco Guzman, Françoise Paris, Charles Sultan, Erica A Eugster; Fulvestrant McCune-Albright study group
Affiliations

Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome

Emily K Sims et al. Int J Pediatr Endocrinol. .

Abstract

Background: McCune-Albright Syndrome (MAS) is usually characterized by the triad of precocious puberty (PP), fibrous dysplasia, and café au lait spots. Previous treatments investigated for PP have included aromatase inhibitors and the estrogen receptor modulator, tamoxifen. Although some agents have been partially effective, the optimal pharmacologic treatment of PP in girls with MAS has not been identified. The objective of this study was to evaluate the safety and efficacy of fulvestrant (FaslodexTM), a pure estrogen receptor antagonist, in girls with progressive precocious puberty (PP) associated with McCune-Albright Syndrome (MAS).

Methods: In this prospective international multicenter trial, thirty girls ≤ 10 years old with MAS and progressive PP received fulvestrant 4 mg/kg via monthly intramuscular injections for 12 months. Changes in vaginal bleeding, rates of bone age advancement, growth velocity, Tanner staging, predicted adult heights, and uterine and ovarian volumes were measured.

Results: Median vaginal bleeding days decreased from 12.0 days per year to 1.0 day per year, with a median change in frequency of -3.6 days, (95% confidence interval (CI) -10.10, 0.00; p = 0.0146). Of patients with baseline bleeding, 74% experienced a ≥50% reduction in bleeding, and 35% experienced complete cessation during the study period (95% CI 51.6%, 89.8%; 16.4%, 57.3%, respectively). Average rates of bone age advancement (ΔBA/ΔCA) decreased from 1.99 pre-treatment to 1.06 on treatment (mean change -0.93, 95% CI -1.43, -0.43; p = 0.0007). No significant changes in uterine volumes or other endpoints or serious adverse events occurred.

Conclusions: Fulvestrant was well tolerated and moderately effective in decreasing vaginal bleeding and rates of skeletal maturation in girls with MAS. Longer-term studies aimed at further defining potential benefits and risks of this novel therapeutic approach in girls with MAS are needed.

Trial registration: NCT00278915.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Change in frequency of annualized days of vaginal bleeding from pre-treatment to on- treatment period. Bleeding was calculated based on worst-case scenario (assuming bleeding occurred on days without diary data available). *Patients with one or more missing days of data which were counted as bleeding days. †Patients withdrew from study due to worsening of condition.
Figure 2
Figure 2
Change in skeletal maturation. Rate of skeletal maturation during pre-treatment (change in BA during 6 months prior to treatment) and on-treatment period (change in BA during the 12 months of study) by patient (n = 30).
See this image and copyright information in PMC

References

    1. McCune D. Osteitis fibrosa cystica; the case of a nine year old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Am J Dis Child. 1936;52:743–744.
    1. Albright F, Butler AM, Hampton AO, Smith P. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females: report of five cases. N Engl J Med. 1937;216:727–776. doi: 10.1056/NEJM193704292161701. - DOI
    1. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325(24):1688–1695. doi: 10.1056/NEJM199112123252403. - DOI - PubMed
    1. Happle R. The McCune-Albright syndrome: a lethal gene surviving by mosaicism. Clin Genet. 1986;29(4):321–324. - PubMed
    1. Haddad N, Eugster E. An update on the treatment of precocious puberty in McCune-Albright syndrome and testotoxicosis. J Pediatr Endocrinol Metab. 2007;20(6):653–661. - PubMed

Associated data